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A B S T R A C T
Purpose
To evaluate the impact of DNMT3A mutations on outcome in younger patients with cytogenetic
intermediate-risk acute myeloid leukemia.
Patients and Methods
Diagnostic samples from 914 patients (97%  60 years old) were screened for mutations in
DNMT3A exons 13 to 23. Clinical outcome was evaluated according to presence or absence of a
mutation and stratified according to type of mutation (R882, non-R882 missense, or truncation).
Results
DNMT3A mutations (DNMT3AMUT) were identified in 272 patients (30%) and associated with a
poorer prognosis than wild-type DNMT3A, but the difference was only seen when the results
were stratified according to NPM1 genotype. This example of Simpson’s paradox results from the
high coincidence of DNMT3A and NPM1 mutations (80% of patients with DNMT3AMUT had NPM1
mutations), where the two mutations have opposing prognostic impact. In the stratified analyses,
relapse in patients with DNMT3AMUT was higher (hazard ratio, 1.35; 95% CI, 1.07 to 1.72; P 
.01), and overall survival was lower (hazard ratio, 1.37; 95% CI, 1.12 to 1.87; P .002). The impact
of DNMT3AMUT did not differ according to NPM1 genotype (test for heterogeneity: relapse, P 
.4; overall survival, P  .9). Further analysis according to the type of DNMT3A mutation indicated
that outcome was comparable in patients with R882 and non-R882 missense mutants, whereas
in those with truncation mutants, it was comparable to wild-type DNMT3A.
Conclusion
These data confirm that presence of a DNMT3A mutation should be considered as a poor-risk
prognostic factor, irrespective of the NPM1 genotype, and suggest that further consideration
should be given to the type of DNMT3A mutation.
J Clin Oncol 33:2072-2083. © 2015 by American Society of Clinical Oncology
INTRODUCTION
The development of high-throughput technologies
has had a major influence on uncovering the molec-
ular landscape of tumors and, in acute myeloid leu-
kemia (AML), has revealed a hitherto unrecognized
degree of complexity and heterogeneity that pres-
ents considerable challenges for the stratification of
risk-directed therapy. Whole-genome/exome se-
quence data from 200 patients with AML showed
that the incidence of the majority of recurrently mu-
tated genes detected was less than 10% of all patients,
but FLT3 internal tandem duplications (FLT3ITD)
and mutations in the NPM1 (NPM1MUT) and DNA
methyltransferase 3A (DNMT3AMUT) genes were
much more frequent, each occurring in more than
25% of patients.1 All three mutations predominate
in patients with cytogenetically intermediate-risk
(IR) AML, and they are often coincident.2-9 FLT3
and NPM1 are now routinely screened at diagnosis,
with general consensus that FLT3ITD is associated
with an adverse impact and NPM1MUT with a favor-
able impact on prognosis,10,11 and patients with
wild-type (WT) FLT3 and NPM1MUT are not rec-
ommended for stem-cell transplantation in first
remission.12,13 The role of DNMT3AMUT in prog-
nostication is less clear. Although most studies have
reported that mutations are associated with worse
overall survival (OS), reviewed in recent meta-
analyses,14,15 the largest study to date that included
1,060 younger adult patients with IR cytogenetics
found that DNMT3AMUT had no significant impact
on survival end points, either overall or in the nor-
mal karyotype (NK) subgroup.9 Furthermore, in
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studies where an adverse impact has been recorded, there are variable
results for the different FLT3/NPM1 genotypic subgroups.3-7,9 Of
particular importance to patient management, there is controversy on
the impact of the mutations in low-risk patients with IR/NK cytoge-
netics and FLT3WTNPM1MUT genotype, with studies reporting either
no impact4,7,9 or adverse impact.5,6
DNMT3A is a DNA methyltransferase that is responsible for de
novo methylation of CpG dinucleotides. It has three conserved func-
tional domains, the C-terminal methyltransferase catalytic domain
encoded by exons 16 to 23, an N-terminal PWWP domain (exons 8
and 9) that binds to specific lysine residues in methylated histones, and
an ADD zinc finger domain (exons 13 to 15) that interacts with
nonmethylated H3K4.16 Mutations were first identified in AML from
array-based or whole-genome/exome sequencing of patient sam-
ples.2,17,18 Missense mutations at residue R882 are particularly fre-
quent, occurring in approximately two thirds of mutated cases.2-9,18
Other mutations are found throughout the gene, predominantly in
exons 13 to 23. They include missense, nonsense, frameshift, and
splice site mutations and are usually heterozygous.
There is limited information on the impact of the different mu-
tations, with reports of either no difference between R882 and non-
R882 mutations2,4,6,7 or variable impact in selected groups8,9 and no
data comparing the impact of missense and truncating mutations,
although they may have differing functional consequences. The major
R882H mutation disrupts the DNMT3A homodimer interface and
acts in a dominant-negative manner, leading to reduced homote-
tramer formation and much lower catalytic activity.19-21 Other mis-
sense mutations also occur at the dimer interface, but some are located
at the tetramer interface and may have more modest effects on cata-
lytic activity but reduce overall methylation.22 Truncating mutations,
however, are more likely to lead to nonsense-mediated decay23 and
haploinsufficiency than dominant-negative activity. In mouse
models, heterozygous Dnmt3a deletion had no apparent effect on
phenotype,24 and primary transplant recipients of Dnmt3a-null he-
matopoietic stem cells did not have evident changes in hematopoie-
sis.25,26 Furthermore, high-resolution methylation analysis has now
shown focal hypomethylation at specific CpG residues in R882-
mutated patients that is not seen in the non–R882-mutated patients,
with a distinct hierarchical clustering of the R882-mutated patients
away from the non–R882-mutated patients.21
Because knowledge of DNMT3A mutations and their impact on
clinical outcome may influence both gene screening strategies and
therapy risk stratification, we have screened samples from a large
cohort of 914 younger adult IR patients in whom there is extensive
follow-up data and evaluated outcome according to the type of
DNMT3A mutation detected.
PATIENTS AND METHODS
Patient Cohort
Genomic DNA was available from diagnostic samples of 914 patients
with IR cytogenetics, as defined by the Medical Research Council classifica-
tion,27 uniformly treated on the United Kingdom Medical Research Council
AML10 and AML12 trials between 1988 and 2002; 54% of samples were from
bone marrow, 44% were from peripheral blood, and for 2%, the source was
not known. Ethical approval for the trials and tissue collection for research was
obtained from the Multi-Centre Research Committee of Wales. Informed
consent was obtained in accordance with the Declaration of Helsinki. Patient
characteristics are listed in Table 1. Median age at presentation was 43 years
(range, 15 to 68 years); only 24 patients (3%) were 60 years old. All samples
had known FLT3ITD and FLT3 tyrosine kinase domain, NPM1, CCAAT/
enhancer binding protein- (CEBPA), and isocitrate dehydrogenase (IDH) 1
and IDH2 genotype.28-32 Compared with the 1,996 IR patients treated on these
trials who were not included in the study, the investigated patients had signif-
icantly higher WBC counts (P .001) but no differences in median age, sex,
incidence of secondary disease, or proportion who received a stem-cell trans-
plantation in first remission (Appendix Table A1, online only). The investi-
gated cohort, compared with patients not included in the study, had a
borderline higher remission rate (87% v 84%, respectively; P  .03) and
better 5-year OS (39% v 34%, respectively; P  .02), but there was no
significant difference in cumulative incidence of relapse (CIR; 49% v 53%,
respectively; P .1).
DNMT3A Screening and Mutant Quantification
Amplicons of DNMT3A exons 13 to 23 were screened by denaturing
high-performance liquid chromatography (Appendix and Appendix Table
A2, online only). The common R882H and R882C mutations were confirmed
by restriction enzyme digestion; other samples with abnormal chromatograms
were sequenced. The relative mutant level for samples with R882H and R882C
mutations was quantified using pyrosequencing and expressed as a relative
proportion of total DNMT3A alleles.
Statistical Methods and Clinical End Points
Details of the trial protocols have been previously published.33,34 The
AML12 trial is registered at http://www.controlled-trials.com under
ISRCTN17833622. Of the 914 patients, 100 underwent allogeneic transplan-
tation from a sibling donor and 17 underwent transplantation from a matched
unrelated donor in first remission.
Clinical end points are defined in the Appendix. Mantel-Haenszel and2
tests were used to test for differences in demographic and clinical data by
DNMT3A status. Kaplan-Meier curves were constructed for survival data and
compared by means of the log-rank test, with standard tests for heterogeneity
between subgroups.35 Surviving patients were censored on August 9, 2010,
with follow-up complete for 98% of patients. Median follow-up was 13.4 years
(range, 5.2 to 21.9 years). Multivariable logistic regression analysis was used to
find the factors most closely associated with complete remission, and multi-
variable Cox analysis was used for CIR and OS. Results were adjusted for age,
WHO performance status, log(WBC), secondary disease, FLT3ITD, and NPM1
genotype. Odds ratios or hazard ratios (HRs) and 95% CIs are quoted for end
points. In all cases, a ratio of less than 1 indicates benefit for a mutation. All P
values are two-tailed.
RESULTS
DNMT3A Mutation Analysis
Overall, 278 mutations were detected in 272 (30%) of 914 pa-
tients (Fig 1A and Appendix Table A3, online only); 175 (63%) were
missense R882 mutations. The remaining mutations were distributed
throughout the gene and included 63 missense mutations, 37 muta-
tions classified as truncations (12 nonsense, 13 frameshift, 12 at splice
sites), and three in-frame deletions. Six patients had homozygous
mutations, all except one non-R882 missense substitutions, and six
patients had two mutations, all non-R882. Therefore, of the 272
DNMT3AMUT patients, 175 (64%) had R882 mutations, 59 (22%) had
non-R882 missense mutations, 35 (13%) had truncations or in-frame
deletions, and three (1%) had two mutations of differing types.
The median DNMT3A mutant level for 172 patients with R882H
(n123) or R882C (n49) mutations was 47% (range, 15% to 85%;
Appendix Fig A1, online only), indicative of a heterozygous mutation
in nearly all cells. NPM1MUT levels were available from 147 of these
Impact of DNMT3A Mutations in AML
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patients, and of the 12 patients with a DNMT3AMUT level less than
35%, nine also had an NPM1MUT level less than 35% (Fig 1B). Assum-
ing that an NPM1 mutation is found in virtually all leukemic cells, this
suggests that the instances of low-level DNMT3AMUT were a result of
nonleukemic cell contamination rather than the mutation being pres-
ent only in a subclone of leukemic cells.
Patient Characteristics According to
DNMT3A Genotype
DNMT3AMUT patients were significantly older than DNMT3AWT
patients (P .001) and more likely to be female (P .004) and have a
higher presenting WBC (P  .001; Table 1). There was a significant
difference across morphologic subgroups (P .001), with higher rates in
M4(40%)andM5(43%),whichrepresented37%and22%,respectively,
of all DNMT3AMUT patients. DNMT3AMUT patients were significantly
more likely than DNMT3AWT patients to have an NK rather than an IR
abnormal karyotype (P .001). Coincidence with other recurrent muta-
tions showed a positive correlation between DNMT3AMUT and
NPM1MUT (P .001), FLT3ITD (P .001), IDH1MUT (P .004), and
IDH2MUT (P .01),but a negative correlation with CEBPAMUT (P
.001; Table 1; Fig 1C). Of note, 80% of the DNMT3AMUT samples
were NPM1MUT, 37% were FLT3ITDNPM1MUT, and 43% were
FLT3ITD-WTNPM1MUT. Conversely, 47% of NPM1MUT samples
were DNMT3AMUT.
There was no difference in age, sex, and type of leukemia
between DNMT3AMUT patients with R882 (DNMT3AR882) and
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Fig 1. DNMT3A mutations detected: mutant type, level, and coincidence with other recurrent mutations. (A) Exonic location and the mutant type of all detected
mutations. The amino acid (AA) given is the first AA of the exon, except for the last AA (912). (*) In-frame deletions. (B) Comparison of DNMT3A and NPM1 mutant
levels in 147 patients with R882H or R882C mutations. The dotted line indicates a mutant level of 35%. (C) Coincidence of other mutations in the cohort of 272
DNMT3A-mutated patients. DM, double mutant; ITD, internal tandem duplication; SM, single mutant; TKD, tyrosine kinase domain; WT, wild type.
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DNMT3AMUT patients with other mutations (DNMT3Anon-R882),
irrespective of the type of non-R882 mutation (Table 1). However,
DNMT3AR882 patients had a significantly higher WBC than
DNMT3Anon-R882 patients (P  .005) and a significantly higher
correlation with NPM1MUT (P  .01). In the DNMT3Anon-R882
patients, those with missense mutations had a higher median WBC
and more coincidence with NPM1MUT, FLT3ITD, and IDH1MUT
than those with truncations (Table 1).
BA
0
Cu
m
ul
at
iv
e 
In
ci
de
nc
e
of
 R
el
ap
se
 (%
)
Time Since CR (years)
No. at risk
DNMT3A WT 545 324 243 220 210 201 194 189 185 170 152
DNMT3A mutant 246 141 112 97 92 88 81 76 75 68 58
100
80
60
40
20
2 4 6 8 101 3 5 7 9
P = .7
 No. No. Events
 Patients Obs.  Exp. 
DNMT3A WT 545 276 279.8
DNMT3A mutant 246 127 123.2
0
Cu
m
ul
at
iv
e 
In
ci
de
nc
e
of
 R
el
ap
se
 (%
)
Time Since CR (years)
No. at risk
DNMT3A WT 224 163 127 118 115 111 106 106 105 98 88
DNMT3A mutant 202 118 99 88 85 82 76 71 70 63 53
100
80
60
40
20
2 4 6 8 101 3 5 7 9
P = .01
 No. No. Events
 Patients Obs.  Exp. 
DNMT3A WT 224 90 107.2
DNMT3A mutant 202 100 82.8
DC
0
Cu
m
ul
at
iv
e 
In
ci
de
nc
e
of
 R
el
ap
se
 (%
)
Time Since CR (years)
No. at risk
DNMT3A WT 321 161 116 102 95 90 88 83 80 72 64
DNMT3A mutant 44 23 13 9 7 6 5 5 5 5 5
100
80
60
40
20
2 4 6 8 101 3 5 7 9
P = .5
 No. No. Events
 Patients Obs.  Exp. 
DNMT3A WT 321 186 189.2
DNMT3A mutant 44 27 23.8
0
Ov
er
al
l S
ur
vi
va
l (
%
)
Time Since Study Entry (years)
No. at risk
DNMT3A WT 642 434 326 280 266 252 238 231 224 205 182
DNMT3A mutant 272 177 139 118 113 108 99 95 91 82 70
100
80
60
40
20
2 4 6 8 101 3 5 7 9
P = .7
 No. No. Events
 Patients Obs.  Exp. 
DNMT3A WT 642 430 433.8
DNMT3A mutant 272 186 182.2
FE
0
Ov
er
al
l S
ur
vi
va
l (
%
)
Time Since Study Entry (years)
No. at risk
DNMT3A WT 241 184 155 140 138 134 130 128 125 115 105
DNMT3A mutant 218 148 118 104 102 98 92 88 84 75 63
100
80
60
40
20
2 4 6 8 101 3 5 7 9
P = .01
 No. No. Events
 Patients Obs.  Exp. 
DNMT3A WT 241 126 147.3
DNMT3A mutant 218 140 118.7
0
Ov
er
al
l S
ur
vi
va
l (
%
)
Time Since Study Entry (years)
No. at risk
DNMT3A WT 401 250 171 140 128 118 108 103 99 90 77
DNMT3A mutant 54 29 21 14 11 10 7 7 7 7 7
100
80
60
40
20
2 4 6 8 101 3 5 7 9
P = .10
 No. No. Events
 Patients Obs.  Exp. 
DNMT3A WT 401 304 313.6
DNMT3A mutant 54 46 36.4
51%
58%
61%
40%
49%
34%
33%
50%
38%
25%
15%
Fig 2. Kaplan-Meier curves for outcome stratified according to DNMT3A genotype. Cumulative incidence of relapse in (A) the total cohort, (B) NPM1MUT patients,
and (C) NPM1WT patients. Overall survival in (D) the total cohort, (E) NPM1MUT patients, and (F) NPM1WT patients. CR, complete remission; Exp., expected; MUT,
mutation; Obs., observed; WT, wild type.
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Response to Therapy and Long-Term Outcome
Stratified According to DNMT3A Genotype
There was a slightly but significantly higher remission rate in
DNMT3AMUT patients than DNMT3AWT patients (90% v 85%, re-
spectively; P .03). However, this can probably be attributed to the
association with NPM1MUT, and the significance was not maintained
in multivariable analysis taking into account patient characteristics
and other molecular markers (odds ratio, 0.74; 95% CI, 0.43 to 1.28;
P .3; Appendix Table A4, online only). In the total group, neither
CIR nor OS differed according to DNMT3A genotype (P .7 for both;
Figs 2A and 2D). However, these results suggesting that DNMT3A muta-
tions are not associated with a poor prognosis must be interpreted with
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Fig 3. Forest plots for the impact of a DNMT3A mutation on outcome in different molecular groups. (A) Relapse. (B) Overall survival. E, expected; ITD, internal
tandem duplication; NS, not significant; O, observed; OR, odds ratio; TKD, tyrosine kinase domain; WT, wild type.
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cautionbecauseofthehighlevelofconcordancewithNPM1MUT,whichis
associated with a good prognosis. Therefore, we performed a subgroup
analysis of NPM1MUT and NPM1WT patients.
The remission rate in NPM1MUT patients was 93% for both
DNMT3AMUT and DNMT3AWT; in NPM1WT patients, the remission
rates were 81% and 80% for DNMT3AMUT and DNMT3AWT, respec-
tively. DNMT3AMUT was associated with higher CIR in both
NPM1MUT and NPM1WT patients when analyzed separately (Figs 2B
and 2C). Although this was not significant for the NPM1WT
DNMT3AMUT patients, in the analysis stratified for NPM1 genotype,
the overall impact of DNMT3AMUT was significantly adverse (HR,
1.35; 95% CI, 1.07 to 1.72; P  .01), and testing for heterogeneity
showed that the impact did not significantly differ between NPM1MUT
and NPM1WT patients (P .4; Fig 3A). There was no difference in the
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Fig 3. (continued).
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impact stratified according to FLT3ITD status. Further analysis of the
four subgroups defined by NPM1 and FLT3ITD genotype similarly
showed no heterogeneity between the groups of the poor prognostic
impact on CIR associated with DNMT3AMUT (P  .7; Fig 3A). In
accord with these results, DNMT3AMUT patients had worse OS than
DNMT3AWT patients with either NPM1MUT or NPM1WT genotype
(Figs 2E and 2F), and although not significant for the NPM1WT
DNMT3AMUT patients, the overall impact in the stratified analysis was
highly significant (HR, 1.37; 95% CI, 1.12 to 1.87; P .002; Fig 3B).
There was no evidence of heterogeneity of the impact of a DNMT3A
mutation between NPM1MUT and NPM1WT patients (P  .9) or
between the four NPM1/FLT3ITD genotypes (P .3; Fig 3B). Of note,
four of the 54 patients with double CEBPA mutations (CEBPADM)
were also DNMT3AMUT. All four patients attained remission but
experienced relapse, which represents a significantly higher CIR com-
pared with CEBPADMDNMT3AWT patients (P .03; Fig 3A). There
was also a trend to lower OS in these CEBPADMDNMT3AMUT patients
(P .1; Fig 3B).
In multivariable analysis, DNMT3AMUT was a significant adverse
risk factor for CIR (HR, 1.27; 95% CI, 1.01 to 1.61; P  .04) and a
borderline adverse factor for OS (HR, 1.19; 95% CI, 0.98 to 1.45; P
.1; Appendix Table A4). In a forward selection model considering all
clinically relevant factors, DNMT3A genotype entered as a significant
factor for relapse but not complete remission or OS (Appendix Table
A5, online only).
Outcome Stratified According to Type of
DNMT3A Mutation
To assess the impact of different DNMT3A mutations, outcome
was considered according to the type of mutation—R882, non-R882
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Fig 4. Kaplan-Meier curves for outcome stratified according to type of DNMT3A mutation. Cumulative incidence of relapse in (A) NPM1MUT patients and (B) NPM1WT
patients. Overall survival in (C) NPM1MUT patients and (D) NPM1WT patients. CR, complete remission; Exp., expected; Obs., observed; WT, wild type.
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missense, or truncation. Three patients were excluded from the anal-
ysis because they had two mutations of differing types.
The remission rate did not differ significantly according to mu-
tation type (P .4 across the three groups) in either NPM1MUT (P
.2) or NPM1WT (P  .6) patients. CIR was higher in DNMT3AR882
patients than DNMT3AWT patients with either NPM1MUT or
NPM1WT genotype, whereas patients with truncations had similar
CIR to those with DNMT3AWT among NPM1MUT patients and lower
CIR than those with DNMT3AWT among NPM1WT patients (Figs 4A
and 4B). Non-R882 missense mutations were associated with
higher CIR than DNMT3AWT in NPM1MUT patients, equivalent to
DNMT3AR882 patients, and similar CIR to DNMT3AWT in NPM1WT
patients. In accord with this, patients with DNMT3AR882 had worse
OS than patients with DNMT3AWT and either NPM1MUT or NPM1WT
genotype (Figs 4C and 4D). Truncations were associated with nonsig-
nificantly better OS in NPM1MUT patients and were similar to
DNMT3AWT in NPM1WT patients. Non-R882 missense mutations
were associated with poorer OS in NPM1MUT patients, similar to R882
mutations, but seemed to have a lesser impact in NPM1WT patients,
although there were only 12 patients in this category.
Because these results suggested that DNMT3A truncation and
missense mutations may differ in their impact on outcome, the data
were reanalyzed excluding patients with truncations. The results were
comparable to the initial results, but the differences were of slightly
greater significance (Figs 5A to 5D).
DISCUSSION
In this large cohort of cytogenetically IR younger patients with AML, a
DNMT3A mutation was associated with poorer prognosis, but this
difference was only observed if the results were analyzed separately
according to NPM1 genotype, where worse OS was seen in
DNMT3AMUT patients with both NPM1MUT and NPM1WT genotype.
This is an example of Simpson’s paradox.36 It results from the strong
association between DNMT3A and NPM1 mutations and the oppos-
ing prognostic impact of the two mutants. In our cohort, 80% of
DNMT3AMUT patients were also NPM1MUT, which leads to a marked
inequality in the proportion of DNMT3AMUT in the NPM1MUT and
NPM1WT patients. Because outcome of the total group reflects the
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Fig 5. Kaplan-Meier curves for outcome stratified according to DNMT3A genotype excluding truncation mutations. Cumulative incidence of relapse in (A) NPM1MUT
patients and (B) NPM1WT patients. Overall survival in (C) NPM1MUT patients and (D) NPM1WT patients. CR, complete remission; Exp., expected; Obs., observed; WT,
wild type.
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relative proportion of the different genotypic subgroups, the effect
that is seen separately in the groups is masked when data from the two
groups are combined. This is illustrated in Appendix Table A6 (online
only). This paradox may explain, at least in part, some of the differ-
ences reported to date in studies examining the prognostic impact of
DNMT3A mutations, in particular where the genotypic subgroups are
small and likely to be less statistically robust.3-7,9 Although there was a
significant association between DNMT3AMUT and FLT3ITD (41% of
DNMT3AMUT patients were FLT3ITD), no such differences were ob-
served when DNMT3AMUT patients were stratified according to
FLT3ITD status because both are associated with poorer outcome.
Studies have shown that different mutations within the same
gene may be associated with variable patient characteristics and out-
come (eg, IDH2 R140 and R172 mutations).32,37 Therefore, consider-
ation needs to be given to the variety of mutations identified in the
DNMT3A gene and their potentially differing functional conse-
quences. In our cohort, 64% of DNMT3AMUT patients had a mutation
at residue R882, comparable to the incidence reported in other studies
(mean, 68%; range, 60% to 83%; test for heterogeneity, P .7).2,4-9,38
However, the remaining mutations were scattered across the zinc
finger and methyltransferase domains and included not only other
missense mutations (22% of mutated patients), but also trunca-
tions (13%). Analysis in the three mutant categories suggested that,
whereas R882 and non-R882 missense mutations were associated
with a similar adverse outcome, the truncations seemed to have a
different functional impact on the R882 mutations and should be
considered as equivalent to DNMT3AWT from a prognostic stand-
point. These data require corroboration from other large cohorts,
because there were only 35 patients with a truncation, which there-
fore results in limited statistical power when split into the
NPM1MUT and NPM1WT groups. If total loss of protein from the
mutated allele leads to haploinsufficiency, then the data are com-
patible with the lack of impact on hematopoiesis observed for
Dnmt3a loss in mouse models,24-26 rather than the dominant-
negative effect that has been demonstrated for the R882 mutant.20
However, it does raise the issue of the role of such mutations in
leukemogenesis, and further studies will be required to investigate
this.
For prognostication purposes, combined analysis of the patients
with non-R882 missense mutations suggested that they should be
considered together with R882-mutated patients as having worse out-
come than DNMT3AWT patients. However, most are unique, and they
comprise a highly heterogeneous group of mutations that disrupt
different domains of the enzyme. Although both the SIFT and Poly-
Phen algorithms predict that the majority of mutations in the zinc
finger and methyltransferase domains are likely to be deleterious,
there is evidence that they differ in their functional and cellular signif-
icance. For example, G543 was the second most commonly mutated
amino acid, detected in 12 patients (4%). It is close to the histone
H3K4 binding surface and does not affect DNA methylation activity
but has increased in vitro ability to interact with histone H3.18 Simi-
larly, differences in mean methylation levels and methylated CpGs
have been reported between patients with R882 and non-R882 muta-
tions.21 More detailed structural and functional analysis of these mu-
tants may thus provide information about the normal roles of
DNMT3A and its interactions with other proteins and how disruption
of these processes may lead to AML.
From a therapeutic viewpoint, our data confirm that
DNMT3AMUT should be treated as a poor-risk factor. This is of par-
ticular relevance to management of patients currently considered
as favorable risk, in particular those with CEBPADM, where
DNMT3AMUT patients were significantly more likely to experience
relapse, and those with NPM1MUTFLT3ITD-WT, where the lack of het-
erogeneity between subgroups indicated that these patients should not
be considered differently from the other NPM1/FLT3 genotype
groups. The adverse outcome associated with the non-R882 missense
mutations also indicates that screening strategies cannot be limited to
analysis of exon 23 alone. It is important to note that the need for
subgroup analysis in prognostication, as in this case, requires cautious
interpretation of the data because of the pitfalls of multiple compari-
sons and potential bias. The controversy over determining how mu-
tant status should be used for risk stratification, even for the three most
commonly mutated genes (DNMT3A, NPM1, and FLT3), reflects the
increasing challenge for determining outcome analysis in the face of
the extensive genotypic heterogeneity and variable interaction be-
tween coincident mutations that is becoming apparent in AML.
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Appendix
Mutation Screening
Polymerase chain reaction (PCR) products for DNMT3A exons 13 to 23 were amplified from genomic DNA using
Optimase Polymerase (Transgenomic, Glasgow, United Kingdom) or Phusion High-Fidelity DNA Polymerase (New England
BioLabs, Hitchin, United Kingdom) according to manufacturer’s instructions, with 35 cycles of amplification and primers
and annealing temperatures as specified (Table A2). Products were denatured, reannealed slowly to allow heteroduplex
formation, and then analyzed on a denaturing high-performance liquid chromatography WAVE platform (Transgenomic,
Glasgow, United Kingdom) at optimal melting temperatures calculated using Transgenomic’s Navigator software (Table A2).
Samples with abnormal WAVE chromatograms were sequenced.
For screening of R882H and R882C mutations, PCR products were prepared using BIOTAQ DNA Polymerase (BIOLINE, London,
United Kingdom) with 32 cycles of amplification and then digested with restriction enzymes (New England BioLabs) according to
manufacturer’s instructions. For R882H, the primers were 23F2 and mismatch primer R882H MM (R; Table A2), and the products were
digested at 65°C for 3 hours with BsaAI. Wild-type products remained uncut (172 base pairs [bp]), and mutant products were digested to
143 29 bp. For R882C, the primers were 23F and 23R, and the products were digested overnight at 37°C with AluI. Wild-type products
remained uncut (318 bp), and mutant products were digested to 193 125 bp.
Quantification of Mutant Level
For R882H and R882C mutations, the relative mutant level was quantified using pyrosequencing of biotinylated PCR products
prepared using GoTaq Hot Start Polymerase (Promega, Southampton, United Kingdom), 50 cycles of amplification, primers Pyro F and
biotinylated Pyro R (Table A2), and an annealing temperature of 63°C. The 184-bp products were sequenced on a PyroMark MD system
(Qiagen, Crawley, United Kingdom) using PyroMark Q96 reagents and protocols (Qiagen) and primer Pyro sequence (Table A2). The
pyrosequencing software calculated mutant level as a percentage of the total alleles for a particular mutation.
Definition of Clinical End Points
Complete remission (CR) was defined as a normocellular bone marrow containing less than 5% blasts and showing evidence of
normal maturation of other marrow elements. CR with incomplete blood count recovery was classified as CR with residual neutropenia
or thrombocytopenia. Persistence of myelodysplastic features did not preclude the diagnosis of CR. Remission failures were classified by
the clinicians as either a result of induction death (death related to treatment and/or hypoplasia within 30 days of trial entry) or resistant
disease (failure to eliminate disease, including partial remission with 5% to 15% blasts in the bone marrow). Where the clinician’s
evaluation was not available, deaths within 30 days of entry were classified as induction deaths, and deaths later than 30 days after entry
were classified as resistant disease. Overall survival was defined as the time from random assignment to death. For patients achieving CR,
cumulative incidence of relapse was the incidence of relapse after CR with death in CR as a competing risk.
Table A1. Comparison of Patients in the Two Trials Who Were Included and Excluded From the Analysis
Characteristic
DNMT3A Cohort
(n  914)
Patients Excluded From
Analysis (n  1,996) P
Median age, years 43 45 .1
Male, % 48 49 .7
Median WBC, 109/L 26.85 11.1  .001
WHO PS  2, % 33 36 .1
Secondary disease, % 7 9 .1
SCT in CR1, % 26 23 .1
CR/CRi, % 87 84 .03
OS at 5 years, % 39 34 .02
CIR at 5 years, % 49 53 .1
Abbreviations: CIR, cumulative incidence of relapse; CR, complete remission; CR1, first complete remission; CRi, complete remission with incomplete hematologic
recovery; OS, overall survival; PS, performance status; SCT, stem-cell transplantation.
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Table A2. Details of Polymerase Chain Reaction Primers and Experimental Conditions for Mutation Screening and Mutant Quantification
Exon and Primer Primer Sequence Size (bp)
Annealing
Temperature (°C)
WAVE
Temperature (°C)
13
F 5=-GCTGGTCTGGTGCTGGGCTC-3= 228 65 63.3
R 5=-CACAGTCAGCCAGAAGGCCGA-3=
14
F 5=-TGAGGCCAGGTGTGGAGCCTC-3= 241 67 64.1
R 5=-TGGGGCCCAGCTAAGGAGACCA-3=
15
F 5=-TCCATTCCAGGTAGCACACCTTG-3= 338 63 63.4, 64.0
R 5=-ACCCTGCGCACAGCTCAGGC-3=
16
F 5=-GACACCGCTGGGCCTGCATC-3= 221 66 62.6
R 5=-ACCATCATTTCGTTTTGCCAGAGTTGC-3=
17
F 5=-TGCCGAGACCAGGGTGCCAG-3= 269 66 64.1
R 5=-CTCCAGGTGCTGAGTGTGCAG-3=
18
F 5=-CTGGGTCTCCTCTCTTTCGTG-3= 252 63 62.6
R 5=-GCACCAGCTGAGAAGGTGGAG-3=
19
F 5=-AGCCACACCACTGTCCTATGC-3= 304 63 61.5, 62.7
R 5=-TCCCCAGCTCCACAATGCAGAT-3=
20
F 5=-CTTTAAGGCTCGACCCCAGCA-3= 241 64 62.2
R 5=-GCTTCCCCACTATGGGTCATC-3=
21
F 5=-GAGGGAGGGGAGTCGTGCA-3= 267 63 62.4
R 5=-GCATTCTCCACACTAGCTGGAGA-3=
22
F 5=-GAGTACCTGGCATATTTGGTAGAC-3= 297 64 59.0
R 5=-CAAGTCAGGTGGGAAAGGCAG-3=
23
F 5=-CCTGCTGTGTGGTTAGACGGCT-3= 318 64 60.8, 63.6
R 5=-CTCTCCATCCTCATGTTCTTGGTG-3=
F2 5=-CTGGTCCTCCGGGTCCTGC-3= 172 64 NA
R882H MM (R) 5=-GACCGGCCCAGCAGTCTCTGCCTCGCCACG-3=
Pyro F 5=-TGTGTGGTTAGACGGCTTCC-3= 184 63 NA
Pyro R (biotin) 5=-GAAGAGGTGGCGGATGACT-3=
Pyro sequence 5=-TGACGTCTCCAACATGA-3=
Abbreviations: bp, base pair; F, forward; NA, not applicable; R, reverse.
Mismatch underlined.
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Table A4. Multivariable Analysis of Outcome in the Total Cohort
Outcome
MUT v WT
P
R882 v Others R882 v Non-R882
Missense v Truncation, PHR (95% CI) P
WT v R882 v
Others
WT v R882 v Non-R882
Missense v Truncation HR (95% CI) P
CR/CRi 0.74 (0.43 to 1.28) .3 .2 .4 1.97 (0.67 to 5.77) .2 .5
OS 1.19 (0.98 to 1.45) .1 .1 .1 1.19 (0.87 to 1.64) .3 .2
CIR 1.27 (1.01 to 1.61) .04 .1 .05 1.25 (0.85 to 1.85) .3 .2
NOTE: Results were adjusted for age, WHO performance status, log(WBC), secondary disease, FLT3ITD, and NPM1 genotype.
Abbreviations: CIR, cumulative incidence of relapse; CR, complete remission; CRi, complete remission with incomplete hematologic recovery; HR, hazard ratio;
MUT, mutant; OS, overall survival; WT, wild type.
Table A5. Significant Variables in Order of Entry in a Forward Selection Model
Variable HR (95% CI) P
CR
NPM1MUT 0.21 (0.13 to 0.34)  .001
Age 1.05 (1.03 to 1.07)  .001
WHO PS 1.52 (1.26 to 1.83)  .001
Log(WBC) 2.19 (1.52 to 3.14)  .001
Secondary disease 2.51 (1.31 to 4.81) .005
CIR
FLT3ITD 2.14 (1.73 to 2.65)  .001
NPM1MUT 0.39 (0.31 to 0.49)  .001
Age 1.01 (1.00 to 1.02) .003
CEBPADM 0.57 (0.36 to 0.89) .01
DNMT3AMUT 1.27 (1.00 to 1.61) .05
OS
NPM1MUT 0.42 (0.35 to 0.50)  .001
Age 1.02 (1.02 to 1.03)  .001
FLT3ITD 1.55 (1.30 to 1.85)  .001
WHO PS 1.13 (1.05 to 1.22)  .001
CEBPADM 0.43 (0.28 to 0.65)  .001
Log(WBC) 1.26 (1.10 to 1.45) .001
NOTE. Models were fitted using forward selection, with variables added to the model if they had a P  .05, derived using the deviance statistic. Variables entered
were age, WHO PS, log(WBC), secondary disease, FLT3ITD, FLT3TKD, NPM1, CEBPADM, IDH1, IDH2, and DNMT3A genotype. DNMT3A was entered as mutant/not,
WT v R882 v other, WT v R882, and missense v truncation.
Abbreviations: CIR, cumulative incidence of relapse; CR, complete remission; DM, double mutant; HR, hazard ratio; ITD, internal tandem duplication; MUT, mutant;
OS, overall survival; PS, performance status; TKD, tyrosine kinase domain; WT, wild type.
Table A6. Contingency Table for OS in the Different Genotype Groups
Genotype
DNMT3AWT DNMT3AMUT
Total No. of
Patients
No. of Patients (% of
DNMT3A subgroup)
Observed 10-Year OS
Rate (%)
No. of Patients (% of
DNMT3A subgroup)
Observed 10-Year OS
Rate (%)
NPM1WT 401 (62) 25 54 (20) 15 455
NPM1MUT 241 (38) 50 218 (80) 38 459
Total 642 272 914
NOTE. The survival for each DNMT3A group (DNMT3AWT and DNMT3AMUT) is obtained by adding together the proportion of NPM1WT patients multiplied by their
survival and the proportion of NPM1MUT patients multiplied by their survival. For DNMT3AWT, OS  (0.62  25%)  (0.38  50%)  34%. For DNMT3AMUT, OS 
(0.20  15%)  (0.80  38%)  33%.
Abbreviations: MUT, mutant; OS, overall survival; WT, wild type.
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Fig A1. Distribution of relative mutant level quantified in 172 patients with DNMT3A R882H or R882C mutations.
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